Skip to main content

REVIEW article

Front. Cell Dev. Biol.
Sec. Cancer Cell Biology
Volume 13 - 2025 | doi: 10.3389/fcell.2025.1522873

Ferroptosis and Noncoding RNAs: Exploring Mechanisms in Lung Cancer Treatment

Provisionally accepted
Zohreh Rezaei Zohreh Rezaei 1*Nadi Rostami Ravari Nadi Rostami Ravari 2Farzad Sadri Farzad Sadri 3Mohammad Ali Mahdiabadi Mohammad Ali Mahdiabadi 3Yaser Mohammadi Yaser Mohammadi 4Zahra Ourang Zahra Ourang 5
  • 1 University of Sistan and Baluchestan, Zahedan, Iran
  • 2 Department of Animal Science Researches, Agriculture and Natural Resources Education and Research Center of Kerman, Agriculture and Natural Resources Education and Research Organization (AREEO), Kerman, Iran
  • 3 Birjand University of Medical Sciences, Birjand, South Khorasan, Iran
  • 4 Iran University of Medical Sciences, Tehran, Tehran, Iran
  • 5 Arak University of Medical Sciences, Arak, Markazi, Iran

The final, formatted version of the article will be published soon.

    Lung cancer (LC) is a highly prevalent and deadly type of cancer characterized by intricate molecular pathways that drive tumor development, metastasis, and resistance to conventional treatments. Recently, ferroptosis, a controlled mechanism of cell death instigated by irondependent lipid peroxidation, has gained attention for its role in LC progression and treatment.Noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), are emerging as key modulators of ferroptosis, significantly influencing LC biology. This review explores how ncRNAs control ferroptotic pathways and affect tumor growth, metastasis, and therapy resistance in LC. By understanding the dual functions of ncRNAs in both activating and inhibiting ferroptosis, we aim to uncover new therapeutic targets and strategies for LC. These insights provide a promising direction for the development of ncRNA-based treatments designed to induce ferroptosis, potentially improving therapeutic outcomes for patients with LC.

    Keywords: ferroptosis, lung cancer, noncoding RNAs, therapeutic targets, metastasis

    Received: 05 Nov 2024; Accepted: 31 Jan 2025.

    Copyright: © 2025 Rezaei, Rostami Ravari, Sadri, Mahdiabadi, Mohammadi and Ourang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Zohreh Rezaei, University of Sistan and Baluchestan, Zahedan, Iran

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.